Analyst Price Targets — IRWD
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 26, 2026 3:35 pm | Amy Li | Jefferies | $3.70 | $3.60 | StreetInsider | Ironwood Pharmaceuticals (IRWD) PT Raised to $3.70 at Jefferies |
| January 5, 2026 12:27 pm | — | Craig-Hallum | $5.70 | $4.27 | TheFly | Craig-Hallum upgrades Ironwood to Buy following 2026 guidance |
| January 4, 2026 11:22 pm | — | Wells Fargo | $5.00 | $4.27 | TheFly | Ironwood price target raised to $5 from $3 at Wells Fargo |
| November 26, 2025 3:07 pm | — | Craig-Hallum | $3.80 | $3.83 | TheFly | Ironwood price target raised to $3.80 from $1.70 at Craig-Hallum |
| April 14, 2025 3:30 pm | Faisal Khurshid | Leerink Partners | $1.00 | $0.65 | TheFly | Ironwood price target lowered to $1 from $3 at Leerink |
| January 31, 2025 12:05 pm | Mohit Bansal | Wells Fargo | $7.00 | $2.34 | TheFly | Ironwood price target lowered to $7 from $12 at Wells Fargo |
| September 9, 2024 6:26 am | Faisal Khurshid | Leerink Partners | $5.00 | $4.51 | TheFly | Ironwood initiated with a Market Perform at Leerink |
| August 9, 2024 8:24 am | Mohit Bansal | Wells Fargo | $12.00 | $4.05 | TheFly | Ironwood price target lowered to $12 from $14 at Wells Fargo |
| May 22, 2024 7:47 am | David Amsellem | Piper Sandler | $18.00 | $6.82 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD) |
| May 22, 2024 5:13 am | Mohit Bansal | Wells Fargo | $14.00 | $6.78 | StreetInsider | Wells Fargo Reiterates Overweight Rating on Ironwood Pharmaceuticals (IRWD) |
Latest News for IRWD
Ironwood slides 14% in a month on weak Linzess Q4 sales, but strong demand, partnerships, and an upbeat 2026 outlook raise investor optimism.
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report) Director Alexander Denner sold 6,730,800 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $3.05, for a total value of $20,528,940.00. Following the transaction, the director directly owned 9,188,635 shares in the company, valued
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
Ironwood sees Linzess rebounding in 2026 despite soft Q4 results, helped by strong prescription demand and improved net pricing.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IRWD.
U.S. House Trading
No House trades found for IRWD.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.